Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT

Aug 30, 2024Scientific reports

Stanniocalcin-1 may increase resistance to temozolomide chemotherapy in brain tumors by controlling a DNA repair protein

AI simplified

Abstract

High expression of (STC1) is associated with poor prognosis and chemotherapy resistance in glioblastoma.

  • Tumour reproductive cells () demonstrate significantly higher viability when treated with temozolomide (TMZ) compared to standard two-dimensional cultures.
  • RNA-seq analysis revealed upregulated expression of STC1 in TRCs cultured in three-dimensional soft fibrin gels.
  • Clinical data indicate that high STC1 expression correlates with increased glioma grade and resistance to TMZ treatment.
  • Overexpression of STC1 promotes DNA damage resistance in response to TMZ, while its knockdown inhibits this effect.
  • STC1 is suggested to regulate MGMT expression in glioblastoma, highlighting its potential as a therapeutic target.

AI simplified

Key numbers

40–50%
Increase in TMZ resistance
Tumor growth inhibition observed with knockdown and TMZ treatment.
422 patients
Correlation with poor prognosis
Analysis of clinical data from the CGGA database.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • đŸ§˜â€â™‚ïžalways free